These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 31970660)

  • 1. The Most Severe Stage of Chronic Venous Disease: An Update on the Management of Patients with Venous Leg Ulcers.
    Nicolaides AN
    Adv Ther; 2020 Feb; 37(Suppl 1):19-24. PubMed ID: 31970660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Benefits of Micronized Purified Flavonoid Fraction (MPFF) Throughout the Progression of Chronic Venous Disease.
    Nicolaides AN
    Adv Ther; 2020 Feb; 37(Suppl 1):1-5. PubMed ID: 31970659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF).
    Bush R; Comerota A; Meissner M; Raffetto JD; Hahn SR; Freeman K
    Phlebology; 2017 Apr; 32(1_suppl):3-19. PubMed ID: 28211296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials.
    Kakkos SK; Nicolaides AN
    Int Angiol; 2018 Apr; 37(2):143-154. PubMed ID: 29385792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
    Lyseng-Williamson KA; Perry CM
    Drugs; 2003; 63(1):71-100. PubMed ID: 12487623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micronized Purified Flavonoid Fraction (MPFF) for Patients Suffering from Chronic Venous Disease: A Review of New Evidence.
    Ulloa JH
    Adv Ther; 2019 Mar; 36(Suppl 1):20-25. PubMed ID: 30758743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The social and economic burden of venous leg ulcers: focus on the role of micronized purified flavonoid fraction adjuvant therapy.
    Simka M; Majewski E
    Am J Clin Dermatol; 2003; 4(8):573-81. PubMed ID: 12862500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Literature Review of Pharmacological Agents to Improve Venous Leg Ulcer Healing.
    Kitchens BP; Snyder RJ; Cuffy CA
    Wounds; 2020 Jul; 32(7):195-207. PubMed ID: 33166265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From skin disorders to venous leg ulcers: pathophysiology and efficacy of Daflon 500 mg in ulcer healing.
    Coleridge Smith PD
    Angiology; 2003; 54 Suppl 1():S45-50. PubMed ID: 12934756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic venous disease and venous leg ulcers: An evidence-based update.
    Kelechi TJ; Johnson JJ; Yates S
    J Vasc Nurs; 2015 Jun; 33(2):36-46. PubMed ID: 26025146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and cost efficacy of advanced wound care matrices for venous ulcers.
    Hankin CS; Knispel J; Lopes M; Bronstone A; Maus E
    J Manag Care Pharm; 2012 Jun; 18(5):375-84. PubMed ID: 22663170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction.
    Coleridge-Smith P; Lok C; Ramelet AA
    Eur J Vasc Endovasc Surg; 2005 Aug; 30(2):198-208. PubMed ID: 15936227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of guideline-based optimal care for venous leg ulcers in Australia.
    Cheng Q; Gibb M; Graves N; Finlayson K; Pacella RE
    BMC Health Serv Res; 2018 Jun; 18(1):421. PubMed ID: 29880046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of pentoxifylline for chronic venous leg ulcers: study protocol for a multicenter randomized controlled trial in China (ESPECT study).
    Chen L; Gao Y; Liu M; Li Q; Han C; Zhao Y; Li B; Xu J; Dai Y; Li P; Li J; Li Y; Ran X
    Trials; 2023 Aug; 24(1):491. PubMed ID: 37533132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic venous leg ulcers: is topical zinc the answer? A review of the literature.
    O'Connor S; Murphy S
    Adv Skin Wound Care; 2014 Jan; 27(1):35-44; quiz 45-6. PubMed ID: 24343392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of micronized purified flavonoid fraction: an overview.
    Struckmann JR
    J Vasc Res; 1999; 36 Suppl 1():37-41. PubMed ID: 10474049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventions for helping people adhere to compression treatments for venous leg ulceration.
    Weller CD; Buchbinder R; Johnston RV
    Cochrane Database Syst Rev; 2013 Sep; (9):CD008378. PubMed ID: 24009097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced Stages of Chronic Venous Disease: Evolution of Surgical Techniques and Advantages of Associated Medical Treatment.
    Lurie F
    Adv Ther; 2020 Feb; 37(Suppl 1):6-12. PubMed ID: 31981107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Insights for the Appropriate Management of Chronic Venous Disease: A Narrative Review of Implications for the Use of Venoactive Drugs.
    Gianesini S; De Luca L; Feodor T; Taha W; Bozkurt K; Lurie F
    Adv Ther; 2023 Dec; 40(12):5137-5154. PubMed ID: 37768506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Stages of Chronic Venous Disease: Medical Treatment Alone or in Addition to Endovenous Treatments.
    Mansilha A
    Adv Ther; 2020 Feb; 37(Suppl 1):13-18. PubMed ID: 31981108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.